AgomAb Therapeutics (NASDAQ:AGMB) Coverage Initiated by Analysts at Leerink Partners

Leerink Partners started coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a research report sent to investors on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $36.00 price objective on the stock.

Other equities analysts have also issued reports about the company. Morgan Stanley started coverage on AgomAb Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $28.00 price target on the stock. Wall Street Zen upgraded shares of AgomAb Therapeutics to a “hold” rating in a research note on Tuesday, February 17th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $32.00.

AgomAb Therapeutics Stock Performance

Shares of NASDAQ AGMB opened at $15.90 on Tuesday. AgomAb Therapeutics has a 12-month low of $12.66 and a 12-month high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.